These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

842 related items for PubMed ID: 15225220

  • 1. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Mar; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus infection in renal transplant recipients.
    Carstens J, Andersen HK, Spencer E, Madsen M.
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD.
    Transplantation; 2006 Apr 27; 81(8):1106-11. PubMed ID: 16641594
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.
    Clin Transplant; 2004 Apr 27; 18(2):179-85. PubMed ID: 15016133
    [Abstract] [Full Text] [Related]

  • 8. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA, Whimbey E, Champlin R, Abi-Said D, Przepiorka D, Tarrand J, Chan K, Bodey GP, Goodrich JM.
    Bone Marrow Transplant; 1997 Jan 27; 19(1):37-41. PubMed ID: 9012929
    [Abstract] [Full Text] [Related]

  • 9. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.
    J Infect Dis; 2001 Dec 01; 184(11):1461-4. PubMed ID: 11709790
    [Abstract] [Full Text] [Related]

  • 10. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 01; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A, Krok K, Cohen D, Blumberg E, Bloom RD.
    Transplant Proc; 2004 Dec 01; 36(10):3019-24. PubMed ID: 15686685
    [Abstract] [Full Text] [Related]

  • 16. A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y.
    J Antimicrob Chemother; 2005 Mar 01; 55(3):391-4. PubMed ID: 15705636
    [Abstract] [Full Text] [Related]

  • 17. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M, Remport A, Hídvégi M, Péter A, Kóbori L, Telkes G, Fazakas J, Gerlei Z, Sárváry E, Sulyok B, Járay J.
    Transpl Infect Dis; 2005 Jun 01; 7(2):63-7. PubMed ID: 16150092
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Jun 01; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.